Kornimate/medical-research-clean huggingface dataset:
effect of different stretching techniques

Conditions: Cerebral Palsy

Summary: the aim of this study is to investigate the effect of proprioceptive neuromuscular facilitation (pnf) and static stretching techniques on the balance and functional capabilities of children diagnosed with diplegic cerebral palsy (cp).

the aim of this study is to investigate the effect of proprioceptive neuromuscular facilitation (pnf) and static stretching techniques on the balance and functional capabilities of children diagnosed with diplegic cerebral palsy (cp). the study consisted of a group of sixteen children, ranging in age from 8 to 16 years, who were diagnosed with bilateral hip flexor contracture and diplegic cerebral palsy. these children were classified according to the gross motor function classification system (gmfcs) levels i to iii. the children were randomly divided into pnf and static stretching groups. stretching techniques were applied 2 days a week for 4 weeks, with 6 repetitions in each session. the study assessed various parameters, including hip extension range of motion (rom), muscle tone intensity based on the modified ashworth scale, hip flexor shortness as determined by the thomas test, the time up and go (tug) test, balance using the pediatric berg balance scale, and functional status evaluated through the gilette functional walking assessment questionnaire.

Eligibility criteria:
inclusion criteria: * a clinical diagnosis of cp; * age ranging from 6 to 18 years; * no recent administration of botulinum toxin to the lower extremity muscles in the last 6 months; * an iq score of 70 or above; * a gross motor function classification system (gmfcs) value of 1, 2 or 3; * presence of hip flexion contracture; * willingness to participate in the study exclusion criteria: * concomitant diagnoses aside from cp, * presenting with muscle tone ratings of 3 or 4 in the hip muscles according to the modified ashworth scale (mas), * who had undergone tendon lengthening surgery to increase hip flexion

Keywords: pnf static stretching balance functionality
gene therapy follow up protocol for subjects previously enrolled in nci center for immuno-oncology studies

Conditions: Cervical Intraepithelial Neoplasia; Cervical Neoplasms; Oropharyngeal Neoplasms; Squamous Intraepithelial Lesions of the Cervix; Hematologic Malignacies

Summary: background: gene therapy is closely followed by the u.s. food and drug administration (fda). the fda requires researchers to conduct long-term follow-up of people who have had the treatment. this study collects data on people who have had gene therapy and sends it to the fda. the data does not include participants names. objective: to contact current or past participants of gene therapy protocols at least once a year for up to 15 years to ensure they have not had any harmful side effects. eligibility: people aged 18 and older who have had gene therapy in a national cancer institute study design: participants will give their address and telephone number. they will also give and the address and phone number of 1 or 2 other people who will know where they are. for the first year after gene therapy, participants will give blood samples 3 times (at 3, 6, and 12 months). for the next 4 years, they may have a physical exam and laboratory tests with a home physician. they will get a kit to mail in blood samples. or they can visit the nih clinical center. they will be asked if they have had any signs of neurological, autoimmune, or blood disorders, or any new cancers. for years 6 to 15, participants will be contacted yearly via phone or email and asked questions about their health. they may give blood samples. when the participant dies, if researchers think the death was caused by gene therapy, they will ask the participant s family to allow an autopsy.

background: the nci cio conducts clinical trials utilizing gene transfer. the current fda requirements for long term follow up may be up to fifteen years for some products. as this time period is frequently longer than studies are expected to be open, a protocol is necessary to ensure the necessary follow up of these subjects objectives: to facilitate collection of long term follow up information on subjects who have participated in gene transfer studies as required by the u.s. food and drug administration and other regulatory groups eligibility: enrollment on a nci cio treatment protocol for gene therapy. design: patients will undergo physical exams, laboratory evaluations and/or phone follow up as required by the treatment protocol and/or as clinically indicated.

Eligibility criteria:
* inclusion criteria: * subjects who have enrolled on an applicable nci cio gene therapy treatment protocol. age \>= 18 years. note: children are generally excluded from cio gene therapy studies and inclusion on this follow-up study will be limited to 18 years and older. exclusion criteria: -children

Keywords: gene transfer recombinant dna product gamma-retroviral vectors laboratory evaluation natural history
personalized feedback for smokers with elevated anxiety sensitivity

Conditions: Anxiety Disorders; Anxiety; Tobacco Dependence; Smoking, Cigarette; Smoking, Tobacco

Summary: this project will develop and refine a computer-delivered integrated personalized feedback intervention (pfi) that directly addresses smoking and anxiety sensitivity (as). the pfi will focus on feedback about smoking behavior, as, and adaptive coping strategies.

the primary goal of the research study is to investigate the efficacy of a brief, personalized computer-delivered transdiagnostic intervention (pfi) that addresses smoking and anxiety sensitivity (as) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce as and negative affective symptoms, and increase adaptive coping skills compared to a smoking information only control. to address this aim, we will implement a randomized controlled trial that will employ a longitudinal experimental design and involve three stages: (a) phone-screener (pre-screener); (b) baseline appointment consisting of a pre-intervention assessment (eligibility), random assignment to a one-session computer-delivered intervention (pfi versus smoking information control with no personalized feedback), and a post-intervention assessment; (c) 1-month follow-up. assessments will include a multi-method approach, including biological, behavioral, and self-report methods.

Eligibility criteria:
inclusion criteria: * elevated anxiety sensitivity defined as an asi-iii score of at least 17 * daily smoking for at least one year (minimum of 5 cigarettes per day and biochemically confirmed via carbon monoxide \[co\] analysis at least 4 ppm) * not presently engaged in a quit attempt * not currently engaged in mental health treatment * capable of providing informed consent * willing to attend all study visits and comply with the protocol exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners * students for whom you have direct access to/influence on grades * use of other tobacco products * currently suicidal or high suicide risk * currently psychotic or high psychotic risk * insufficient command of english to participate in assessment or treatment

Keywords: anxiety sensitivity tobacco smoking anxiety feedback stress
a study to evaluate the efficacy and safety of als-l1023 in subjects with nash

Conditions: Nonalcoholic Steatohepatitis

Summary: the main objective of this study is to evaluate safety and efficacy of als-l1023 in patients with non-alcoholic steatohepatitis

besides the main objectives, there are other objectives as follows: 1. to evaluate efficacy of als-l1023 for liver fibrosis and steatosis by noninvasive imaging biomarker mri-pdff and mre 2. to determine optimized dose of als-l1023 in nash disease

Eligibility criteria:
inclusion criteria: * men or women ages 19 and over, under 75 years of age * patients diagnosed with nafld on abdominal ultrasonography and mri * patients show presence of hepatic fat fraction as defined by ≥ 8% on mri-pdff and liver stiffness as defined by ≥ 2.5 kpa on mre at screening exclusion criteria: * any subject with current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 2 year prior to screening will be excluded * chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis a, b, alcoholic liver disease * uncontrolled diabetes mellitus as defined by a hba1c ≥ 9.0％ at screening * patients who are allergic or hypersensitive to the drug or its constituents * pregnant or lactating women
oral versus intravenous antibiotics for bone and joint infections (oviva b&j)

Conditions: Bone Infection; Joint Infection

Summary: the study will compare the outcomes of treating bone and joint infections with 6 weeks of intravenous antibiotics with 6 weeks of oral antibiotic treatment. the trial is of antibiotic "strategy" rather than of individual antibiotics. the study will be open label, but the primary outcome will be proven failure of infection treatment, determined by pre-established objective criteria for treatment failure. the null hypothesis tested is that there will be no difference in treatment failure rates.

a long course of antibiotic therapy given by a "drip" (i.e. intravenous) is recommended treatment for many serious bacterial infections. it is costly and inconvenient for the patient to remain hospitalised for therapy, so outpatient antibiotic therapy (opat) programmes have been established in many countries to deliver intravenous antibiotics safely and conveniently. the majority of patients referred to opat programmes have bone and joint infections. however, there is no clear evidence that bone and joint infection really require long courses of intravenous antibiotics rather than oral antibiotics. we will compare the outcome of treatment with intravenous versus oral antibiotic therapy for patients with bone and joint infection. the choice of antibiotic is complex, and antibiotics that are suitable oral choices are often not suitable intravenous choices and vice versa. subjects will therefore be randomized to an oral or intravenous "strategy," rather than to individual antibiotics. outcomes will be determined by pre-established objective criteria for treatment failure. we have conducted a pilot study in one centre (oxford), recruiting approximately 200 patients, and are now expanding to include multi-centre recruitment in the uk, aiming to recruit 1050 patients.

Eligibility criteria:
inclusion criteria: * is willing and able to give informed consent for participation in the study. has a bone and joint infection one of the following categories; 1. native osteomyelitis. 2. native joint septic arthritis. 3. diabetic foot infection with osteomyelitis. 4. prosthetic joint associated infection. 5. discitis/ spinal osteomyelitis/ epidural abscess * has had at least 48 hours, but not more than 7 days, of iv antibiotic therapy already given after definitive surgical management. * has a clinical diagnosis of bacterial infection (caused by any organism excepting mycobacteria). * is clinically stable in the opinion of the study clinicians, has no further interventions to treat acute infection required or planned. exclusion criteria: * has staph aureus bacteraemia. * has suspected bacterial endocarditis. * has suspected mediastinal infection. * has suspected central nervous system infection.

Keywords: oral intravenous antibiotics bone joint infection
imaging of atherosclerosis with 68ga-msa

Conditions: Atherosclerosis; Noninvasive Imaging of Atherosclerosis

Summary: despite of intensive efforts, no specific ath¬erosclerosis-targeting agent labeled with positron emitter is not yet available. fortunately, some scientists made the major advance in the field of clinical atherosclerosis molecular imaging by the metabolic pet reporter agent 18f(fluorine-18)-fdg(fludeoxyglucose) applied to noninvasively image plaque macrophages in carotid arteries. however, coronary and cerebral arterial segments remain uninterpretable due to metabolic property of 18f-fdg. applying the character of the terminal mannose residues of msa binding with the mannose receptors of macrophages in atherosclerosis, we investigate whether 68ga-msa can be a novel agent for non-invasive molecular imaging of atherosclerotic lesion in pet.


Eligibility criteria:
inclusion criteria: * acute coronary syndrome(acute myocardial infarction, unstable angina) * chronic stable angina * control without coronary artery disease exclusion criteria: * pregnancy, allergy to albumin, chronic inflammatory disease

Keywords: positron emission tomography macrophage neomannosyl human serum albumin
analysis of sublingual glycocalyx damage at icu admission to predict risk of death

Conditions: Sepsis; Septic Shock; Endothelial Dysfunction

Summary: the aim of this observative, prospective study is to evaluate if and to what extent glycocalyx damage/microcirculation data at admission in the icu as well as during icu stay can be predictive of mortality and clinical course in patients presenting with the suspicion of sepsis/septic shock. therefore, the enrollment of ca 100 icu patients is planned.


Eligibility criteria:
inclusion criteria: * icu patients admitted to the icu with the clinican suspicion of sepsis/septic shock. exclusion criteria: * underage persons, pregnant women, patients with inflammation or trauma of sublingual mucosa.

Keywords: perfused boundary region pbr sepsis endothelial glycocalyx icu
optical coherence tomography in retinal vein occlusion

Conditions: Optical Coherence Tomography (OCT)

Summary: this study aims to evaluate how optical coherence tomography (oct) can help predict outcomes in patients with retinal vein occlusion (rvo), a condition that affects blood flow in the retina. rvo can cause macular edema, which is swelling in the part of the eye responsible for central vision. the study will use oct scans to assess changes in the retina and how these changes relate to vision improvement over time.

objectives evaluate how oct data can predict visual outcomes by analyzing retinal changes and macular edema characteristics. assess the correlation between baseline oct biomarkers and visual acuity improvements over time. study design type: cross-sectional study. setting: conducted at several eye care centers in egypt. participants inclusion criteria: adults with branch or central rvo, macular edema confirmed by oct, and no prior rvo in the affected eye. exclusion criteria: other retinal diseases, recent intraocular surgery, or significant media opacities. procedures informed consent and history taking. ophthalmologic examination: includes bcva, iop, slit-lamp biomicroscopy, and fundus examination. oct imaging: using nidek rs-330 retina scan duo 2 (sd-oct) to assess macular changes. oct image evaluation: classification of macular edema types and assessment of biomarkers like subretinal fluid and cystoid changes.

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older. patients diagnosed with branch or central retinal vein occlusion. patients with macular edema confirmed by oct due to vein occlusion. patients with no prior history of rvo in the affected eye. exclusion criteria: * presence of other retinal diseases that could affect oct interpretation (e.g., diabetic retinopathy, age-related macular degeneration). history of intraocular surgery within the last three months. presence of significant media opacities (e.g., dense cataract, vitreous hemorrhage) that interfere with oct imaging.

Keywords: oct retinal vein occlusion
risperidone-controlled,multicentre clinical trial of iloperidone in patients with schizophrenia

Conditions: Schizophrenia

Summary: this research is a randomized, double-blind, risperidone-controlled, multicenter clinical study. chinese subjects with ischemic schizophrenia.

subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.

Eligibility criteria:
inclusion criteria: * men and women aged 18 to 65 years with schizophrenia; * panss total score of at least 70 at screening and baseline; * at least 2 more than 4 points in 7 of panss-p; * informed consent. exclusion criteria: * allergy with iloperidone or risperidone; * psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment; * any other primary axis 1 psychiatric diagnosis; * a history of alcohol or drug dependence in recent 1 year; * at imminent risk of harm to self or others; * systolic blood pressure≤90mmhg。

Keywords: iloperidone risperidone panss
comparison of low-intensity extracorporeal shockwave therapy and low-intensity laser effects in adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the aim of this study is to compare the effects of extracorporeal shock wave therapy(eswt) applied in addition to conventional physical therapy on pain, mobility, functional ability, sleep quality and activities of daily living in patients with adhesive capsulitis compared to low-level laser therapy and to investigate whether they are superior to the control group.

in this study, 60 adhesive capsulitis with age range 18-65 who applied to kırsehir ahi evran university training and research hospital were examined.adhesive capsulitis is also called arthrofibrosis, which involves excessive adhesion formation along the glenohumeral joint. it is a disease of unknown etiology and is classified as primary and secondary. primary adhesive capsulitis includes cases of idiopathic origin resulting from chronic inflammation with fibroblast proliferation. secondary adhesive capsulitis, central nervous system involvement, arm immobilized for a long time, trauma or fracture, infectious diseases, etc. includes post-mortem situations. adhesive capsulitis progression is characterized by four stages, each stage presenting a distinctive clinical picture. low-level laser therapy supports cell proliferation and tissue regeneration with its anti-inflammatory and photobiostimulation properties.the pressure waves of eswt pass through fluids and soft tissues and exert their effects in areas of impedance change such as bones and soft tissue spaces. these waves have mechanical and cellular effects. the most important of these effects are temporary damage to the neuronal cell membrane or increased permeability. these mechanisms may facilitate neovascularization and cellular regeneration in tissues.

Eligibility criteria:
inclusion criteria: * male and female patients who have received "adhesive capsulitis" by clinical and examination * patients with loss of range of motion in the capsular pattern (external rotation \> abduction \> internal rotation) will be included in the study. * patients who consent to participate in the study according to the informed consent form will be included in the study. exclusion criteria: * upper extremity injury in the last 6 months * shoulder injection in the last 6 months * existing open wound in the upper extremity area * prior upper extremity surgery * the patient has a systemic infection * uncontrolled hypertension in the patient * inability of the patient to cooperate * the patient's unwillingness to participate in the study * the patient has a malignancy

Keywords: rehabilitation extracorporeal shock wave therapy low-level laser therapy pain
disability level and trunk control in individuals with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: trunk control disorders are frequently encountered in individuals with ms. trunk control is very important for safe and quality movement. impairment of trunk control reduces the level of independence of individuals during activities of daily living. for this reason, it is extremely important to evaluate the trunk in the examination and treatment of individuals. when the literature was examined, it was seen that studies examining trunk control were insufficient. therefore, our study was planned to investigate the relationship between disability level and trunk control in individuals with ms.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * having a definite diagnosis of ms * expanded disability status scale (edss) score of 8.5 and below * not having an attack in the last 3 months exclusion criteria: * having another musculoskeletal, cardiovascular, pulmonary, metabolic, or neurological disease severe enough to preclude participation in the study. * having severe vision and hearing problems * the presence of severe cognitive impairment detected by the physician at a level that prevents the tests from being performed.

Keywords: multiple sclerosis disability level trunk control
antibiotic or not in non-purulent exacerbations of copd: a trial of security and efficacy

Conditions: Chronic Obstructive Pulmonary Disease

Summary: copd is one of the most important causes of morbidity and mortality and supposes a sanitary problem in europe and usa. patients with copd usually have 1-2 episodes of acute exacerbation of copd (aecopd) per year, being these the principal causes of of hospitalizations, respiratory problems and medical visits. after an episode of aecopd, the majority of patients develop a transitory (or permanent) worsening in their quality of life and 50% of them will require a new hospitalization. globally, a 75%\& of the exacerbations might be associated with a respiratory tract infection, and among them, 50% might be related to bacteria and in 45% an evidence of viral infection could be documented. even though the antibiotic treatment might not be useful for a majority of patients with aecopd, is generalized its use(almost an 85% in some series) in hospitalized patients. the non-controlled use of antibiotics in aecopd results in a very expensive disease and raises the rate of resistance of bacteria. the available literature have shown that there's a relation between exacerbations and infections, based on sputum samples. in summary, is well known that at least a 50% of the episodes of aecopd might be associated with pathogenic bacteria in the lower respiratory tract. prescription of antibiotics is wide and generalized in hospitalized patients. clinical trials have shown correlation between aecopd with sputum purulence (which correlates with presence of bacteria), however they've not included non-purulent aecopd, even though they're a significative group of patients hospitalized by this cause too. it's necessary to evaluate the efficacy nor the security of antibiotic treatment in this group of patients in a well designed trial.


Eligibility criteria:
inclusion criteria: * copd diagnosis according to gold guidelines * hospitalization for any acute exacerbation of chronic obstructive pulmonary disease * failure of outpatient treatment * increasing of dyspnea in the last days * comorbidity that causes detriment of respiratory function exclusion criteria: * life expectancy of less than 6 months * mechanical ventilation * cardiovascular condition that causes exacerbation * immunosuppression * pulmonary infiltrates that suggest pneumonia * antibiotic treatment in the last month * pregnancy * ecg with a large qt segment * hypokalemia * hepatic failure or renal failure

Keywords: copd